Key Takeaways
- Shares of Foghorn Therapeutics plummeted 49% to $1.84 following Eli Lilly’s decision to terminate their collaborative cancer drug partnership.
- Both companies agreed to discontinue FHD-909’s development after Phase 1 trial results failed to meet expectations.
- An additional joint program focusing on SMARCA2 degrader development has also been terminated.
- The biotech firm is implementing a workforce reduction of approximately 40% to conserve capital.
- Management projects the company’s available funds will last through the latter half of 2029.
Shares of Foghorn Therapeutics experienced a devastating decline on Thursday following the biotech company’s announcement that its collaboration with pharmaceutical giant Eli Lilly has been dissolved. The stock plunged 49% to $1.84 when trading activity resumed, representing the company’s most significant single-session loss in its history.
Foghorn Therapeutics Inc., FHTX
The company’s shares were temporarily halted prior to the announcement. Once the trading freeze was lifted, shareholders rushed to exit their positions.
The Cambridge-based biotech now carries a market capitalization of approximately $212 million. This represents a dramatic downturn for a company that previously secured a partnership agreement with one of the pharmaceutical industry’s leading corporations.
The decision was made jointly by Foghorn and Lilly to halt advancement of FHD-909 beyond its recently completed Phase 1 dose escalation study.
The experimental therapy was an oral small molecule designed to target SMARCA2, a specific protein. Its mechanism relied on synthetic lethality principles, targeting cancer cells with particular genetic mutations.
The Reason Behind the Program’s Termination
Chief Executive Adrian Gottschalk explained that the compound successfully engaged its intended target. Additionally, the safety profile remained acceptable even at dosage levels exceeding those indicated by preclinical studies.
However, efficacy proved insufficient. Gottschalk noted that the underlying biological relationship between SMARCA2 and SMARCA4 failed to produce clinical responses robust enough to justify continued investment in the therapy’s development.
This represents a disappointing conclusion following extensive research efforts. The setback extends beyond a single discontinued program.
Both organizations have confirmed that an additional collaborative initiative, the Selective SMARCA2 degrader program, will also be discontinued. Foghorn indicated it does not anticipate establishing any new collaborative projects with Lilly moving forward.
The original collaboration was established in December 2021. Lilly’s Loxo Oncology division structured the agreement with $300 million in initial payment along with an $80 million equity investment at $20 per share.
These financial terms appeared highly favorable for Foghorn when initially negotiated. The current trading price represents a significant decline from that $20 investment level.
Foghorn’s Strategic Path Forward
Following the partnership dissolution, Foghorn is implementing aggressive cost-reduction measures. The organization is eliminating nearly 40% of its workforce and reorganizing its operational structure.
Leadership believes these strategic changes will extend the company’s financial runway through the second half of 2029. This provides additional time to advance its continuing pipeline programs.
Foghorn announced it will concentrate resources on wholly-owned proprietary programs. These include a Selective EP300 degrader, a Selective CBP degrader, and an oral therapy targeting immunology and inflammation conditions.
The company also plans to maintain its induced proximity platform as a strategic priority. These initiatives operate independently of Lilly’s financial support.
For Eli Lilly, the market reaction was minimal. The pharmaceutical giant’s shares declined approximately 2%, representing a negligible impact for a company of its scale.
For Foghorn, the implications are far more consequential. The biotech now operates largely independently, depending on existing cash reserves and a significantly reduced workforce to advance its therapeutic pipeline through the coming years.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
